ATE372336T1 - Prozess zur herstellung von pioglitazon via verschiedene zwischenstufen - Google Patents

Prozess zur herstellung von pioglitazon via verschiedene zwischenstufen

Info

Publication number
ATE372336T1
ATE372336T1 AT03753913T AT03753913T ATE372336T1 AT E372336 T1 ATE372336 T1 AT E372336T1 AT 03753913 T AT03753913 T AT 03753913T AT 03753913 T AT03753913 T AT 03753913T AT E372336 T1 ATE372336 T1 AT E372336T1
Authority
AT
Austria
Prior art keywords
via various
intermediate stages
various intermediate
producing
producing pioglitazone
Prior art date
Application number
AT03753913T
Other languages
English (en)
Inventor
Bipin Pandey
Vidya Lohray
Braj Lohray
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Application granted granted Critical
Publication of ATE372336T1 publication Critical patent/ATE372336T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32Sulfur atoms
    • C07D213/34Sulfur atoms to which a second hetero atom is attached
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Epoxy Compounds (AREA)
AT03753913T 2002-07-16 2003-07-15 Prozess zur herstellung von pioglitazon via verschiedene zwischenstufen ATE372336T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN648MU2002 2002-07-16

Publications (1)

Publication Number Publication Date
ATE372336T1 true ATE372336T1 (de) 2007-09-15

Family

ID=30012270

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03753913T ATE372336T1 (de) 2002-07-16 2003-07-15 Prozess zur herstellung von pioglitazon via verschiedene zwischenstufen

Country Status (6)

Country Link
US (5) US7465801B2 (de)
EP (1) EP1521753B1 (de)
AT (1) ATE372336T1 (de)
AU (1) AU2003272072A1 (de)
DE (1) DE60316152D1 (de)
WO (1) WO2004007490A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004007490A2 (en) * 2002-07-16 2004-01-22 Cadila Healthcare Limited A process to prepare pioglitazone via several intermediates.
US8993773B2 (en) 2002-07-16 2015-03-31 Cadila Healthcare Limited Process to prepare pioglitazone via several novel intermediates
CZ297266B6 (cs) * 2004-09-10 2006-10-11 Zentiva, A. S. Zpusob prípravy rosiglitazonu
WO2008075380A2 (en) * 2006-12-21 2008-06-26 Ind-Swift Laboratories Limited Process for the preparation of thiazolidine derivatives
JOP20180077A1 (ar) 2007-06-19 2019-01-30 Kythera Biopharmaceuticals Inc تركيبات وطرق لحمض صفراوي تخليقي
US20080318870A1 (en) 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US8242294B2 (en) 2007-06-19 2012-08-14 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
ES2398313T3 (es) 2007-09-14 2013-03-15 Metabolic Solutions Development Company Llc 5-(4-(2-(3-metoxifenil)-2-oxoetoxi)bencil)tiazolidin-2,4-diona para uso en el tratamiento de la diabetes
US8024889B2 (en) * 2008-06-25 2011-09-27 Brett Bunker Pest control method and apparatus
WO2010105048A1 (en) * 2009-03-12 2010-09-16 Metabolic Solutions Development Company Thiazolidinedione analogues
KR20120092714A (ko) * 2009-12-15 2012-08-21 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 비만 및 다른 대사성 질환의 치료를 위한 ppar 절약형 티아졸리딘디온 및 복합제
KR102029611B1 (ko) 2009-12-15 2019-10-07 씨리우스 테라퓨틱스, 엘엘씨 대사성 질환의 치료를 위한 ppar 절약형 티아졸리딘디온염
KR101164429B1 (ko) 2010-05-25 2012-07-12 (주)부흥산업사 환상 아민 중간체를 이용한 피오글리타존 염산염의 제조 방법
US8596663B2 (en) * 2011-03-29 2013-12-03 Shimano Inc. Fluid flow control structure
WO2012153312A1 (en) 2011-05-11 2012-11-15 Ranbaxy Laboratories Limited Process for the purification of pioglitazone
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
CN109020790B (zh) * 2018-08-16 2021-07-27 苏州大学 一种4-环烷基苯乙酮衍生物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4444179A (en) * 1981-03-02 1984-04-24 Trippi Anthony C Orthopedic tongs
NL8402765A (nl) * 1984-09-11 1986-04-01 Philips Nv Manipulator met zes vrijheidsgraden.
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
AU4104593A (en) 1992-05-05 1993-11-29 Upjohn Company, The A process for producing pioglitazone metabolite
KR100366617B1 (ko) * 2000-03-13 2003-01-09 삼성전자 주식회사 자기 정렬 콘택홀 제조 방법
US7009057B2 (en) 2001-04-26 2006-03-07 Zentiva A.S. Method for obtaining pioglitazone as an antidiabetic agent
WO2004007490A2 (en) 2002-07-16 2004-01-22 Cadila Healthcare Limited A process to prepare pioglitazone via several intermediates.

Also Published As

Publication number Publication date
US20120077848A1 (en) 2012-03-29
US7863300B2 (en) 2011-01-04
US8445685B2 (en) 2013-05-21
US20110021576A1 (en) 2011-01-27
AU2003272072A1 (en) 2004-02-02
US7671207B2 (en) 2010-03-02
US8173816B2 (en) 2012-05-08
DE60316152D1 (de) 2007-10-18
US20060167061A1 (en) 2006-07-27
WO2004007490A2 (en) 2004-01-22
US20080004446A1 (en) 2008-01-03
US20080300282A1 (en) 2008-12-04
EP1521753A2 (de) 2005-04-13
US7465801B2 (en) 2008-12-16
EP1521753B1 (de) 2007-09-05
AU2003272072A8 (en) 2004-02-02
WO2004007490A3 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
ATE372336T1 (de) Prozess zur herstellung von pioglitazon via verschiedene zwischenstufen
HK1089444A1 (en) Dihydropteridinones, method for the production and use thereof in the form of drugs
MXPA05012362A (es) Yodopirazolilcarboxanilidas.
SE0200920D0 (sv) Novel compounds
SE9901875D0 (sv) Novel compounds
MX2007003031A (es) Compuestos heteroarilo para uso como betamimeticos en el tratamiento de enfermedades de vias respiratorias.
ATE306252T1 (de) Verfahren zur herstellung kristalliner partikel zur inhalation
SE0401762D0 (sv) Novel compounds
DE60202958D1 (de) Stabiles polymorph von flibanserin, industrielles verfahren zu dessen herstellung und dessen verwendung zur herstellung von medikamenten
ATE430160T1 (de) Lipopeptid-stereoisomere, verfahren zu ihrer herstellung und nützliche zwischenprodukte
ATE528301T1 (de) Verfahren zur herstellung von substituierten sulfoxidzusammensetzungen
DE602005016282D1 (de) Verfahren zur herstellung von camptothecin-derivaten
DE602004003037D1 (de) Verfahren und zwischenprodukte für die herstellung von emtricitabin
ATE277919T1 (de) Verfahren zur herstellung von baccatin iii- derivativen
ATE386027T1 (de) Verfahren zur herstellung von valsartan
ATE496038T1 (de) Verfahren zur herstellung von quetiapin
DE60103560D1 (de) Prozess zur herstellung von paclitaxel
DE60236303D1 (de) Verfahren zur herstellung von 14-beta-hydroxybaccatin-iii-1,14-carbonat
ATE537160T1 (de) Verfahren zur herstellung von 14beta- hydroxybaccatin-iii-1,14-carbonat
ATE244709T1 (de) Verfahren zur herstellung von benzofuranonoximen
DE50312447D1 (de) Verfahren zur herstellung von 4,6-dichlor-5-fluorpyrimidin
ATE451345T1 (de) Verfahren zur herstellung von optisch aktiven 3- phenylpropionsäurederivaten und folgeprodukte davon
DE50203529D1 (de) Verfahren zur herstellung von desclarithromycin, sowie zwischenprodukte
UA84150C2 (ru) Йодопиразолилкарбоксанилиды, способ их получения, производные йодопиразолилкарбоновой кислоты и средство для борьбы с нежелательными микроорганизмами
WO2004033416A3 (de) Carboxyalkoxy-substituierte acyl-carboxyphenyl-harnstoffderivate, verfahren zu ihre herstellung und ihre verwendung als arzneimittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties